Drugs / enerisant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03267303 | Oct 2017 → Dec 2018 | narcolepsy | Taisho Pharmaceutical Co., Ltd. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enerisant | “Optimal dose determination of enerisant (TS-091) for patients with narcolepsy:” PMID 35193545 ↗ Feb 2022 |
| Known as | TS-091 | “Optimal dose determination of enerisant (TS-091) for patients with narcolepsy:” PMID 35193545 ↗ Feb 2022 |
| Action | Inhibit | “enerisant, a novel H3 antagonist/inverse agonist” PMID 35193545 ↗ Feb 2022 |
| Route | Oral | “Orally taken once daily for 3 weeks” NCT03267303 ↗ |